imprime pgg + cetuximab + irinotecan

Imprime PGG + cetuximab + irinotecan is a combination regimen under clinical investigation for cancer treatment. **Imprime PGG** is an intravenously administered, soluble yeast β-glucan that acts as a pathogen-associated molecular pattern (PAMP) and immunomodulator, enhancing anti-tumor immune responses by activating innate immune cells such as monocytes, neutrophils, macrophages, and natural killer (NK) cells[1][2][4][5]. It requires pre-existing anti-β-glucan antibodies to trigger complement activation (via the classical pathway) leading to immune cell opsonization and subsequent tumor killing, particularly when used with monoclonal antibodies[4]. **Cetuximab** is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), blocking ligand binding and receptor activation, thereby inhibiting tumor cell proliferation. **Irinotecan** is a small-molecule topoisomerase I inhibitor, causing DNA damage and apoptosis in proliferating cells. The combination aims to synergistically enhance antitumor activity by combining immune activation (Imprime PGG), targeted cell surface inhibition (cetuximab), and cytotoxic chemotherapy (irinotecan). The regimen is primarily studied in cancer indications, including metastatic colorectal cancer and breast cancer, in the context of combination immuno-oncology[1][2][4].

Other names

poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose + cetuximab + irinotecan